NRAS and melanoma: Altogether our data demonstrate that co‐targeting BET and MEK elicits potent anti‐tumor effects in highly drug‐resistant NRAS‐mutant melanoma models and support the premise that BETi/MEKi combinations may be a valuable salvage strategy for MAPK and immune checkpoint inhibitor‐resistant tumors (Fig 7).